OmniAb, Inc. (OABI) NASDAQ

Currency In USD

AD

OmniAb, Inc.

Address

5980 Horton Street

EmeryVille, CA 94608

United States of America (the)

Phone

510 250 7800

Sector

Healthcare

Industry

Biotechnology

Employees

89

First IPO Date

September 30, 2021

Key Executives

NameTitlePayYear Born
Matthew W. FoehrPresident, Chief Executive Officer & Director1.07M1973
Kurt A. GustafsonExecutive Vice President of Finance & Chief Financial Officer730,7411968
Charles S. BerkmanChief Legal Officer & Secretary742,0651969
Bill HarrimanSenior Vice President of Antibody Discovery0N/A
Christel IfflandSenior Vice President of Antibody Technologies0N/A
Todd PettingillVice President of Business Development & Strategy0N/A
Cia McCaffreySenior Vice President of People & Talent0N/A
Yasmina Noubia AbdicheSenior Vice President of Exploratory Research0N/A
Bob ChenSenior Vice President of Discovery Systems0N/A
AD

Description

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

AD